Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
Table 2
Changes in the lipids profile.
1-year median (Q1-Q3)
Change from the baseline mean (95% CI)
value
Triglycerides (mmol/L)
1.09 (0.80, 1.57)
−0.77 (−1.56, 0.22)
= 0.0312
Total cholesterol (mmol/L)
2.26 (2.11, 2.45)
−2.50 (−2.98, −2.02)
= 0.0003
HDL cholesterol (mmol/L)
1.06 (0.94, 1.11)
−0.13 (−0.23, 0.03)
= 0.0191
LDL cholesterol (mmol/L)
0.95 (0.85, 1.16)
−2.01 (−2.46, −1.57)
= 0.0003
AI
1.31 (0.90, 1.43)
−1.86 (−2.17, −1.56)
= 0.0003
Compared with baseline using Wilcoxon signed-rank test.